{"id":31464,"date":"2025-04-10T17:10:01","date_gmt":"2025-04-10T11:40:01","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31464"},"modified":"2025-04-10T17:10:02","modified_gmt":"2025-04-10T11:40:02","slug":"medtech-news-for-ventris-medical-orthocell-icu-medical","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical","title":{"rendered":"Ventris Medical Secures Additional FDA Clearance for Backpack\u00ae Bone Graft in Intervertebral Disc Applications; Orthocell Gains FDA 510(k) Clearance for Remplir\u2122; ICU Medical Launches New Infusion Device Category with FDA-Cleared Plum Solo\u2122 and Plum Duo\u2122 IV Pumps; Anaconda Biomed Kicks Off U.S. Enrollment for ATHENA Trial Testing ANA Funnel Catheter in Stroke Care; OrthoPediatrics Expands Scoliosis Portfolio with Launch of Innovative VerteGlide\u2122 System; 3D Systems Powers World\u2019s First On-Site Facial Implant Manufacturing at Point-of-Care"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e5cd5b9049a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e5cd5b9049a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical\/#Ventris_Medical_Received_Additional_FDA_Clearance_for_Backpack%C2%AE_Bone_Graft_in_the_Intervertebral_Disc_Space\" >Ventris Medical Received Additional FDA Clearance for Backpack\u00ae Bone Graft in the Intervertebral Disc Space&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical\/#Orthocell_Received_US_FDA_510k_Clearance_for_Remplir%E2%84%A2_Nerve_Repair_Product_Preparing_for_Market_Launch\" >Orthocell Received US FDA 510(k) Clearance for Remplir\u2122 Nerve Repair Product, Preparing for Market Launch&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical\/#ICU_Medical_Launched_Its_New_Category_of_Infusion_Devices_With_FDA_Clearances_of_Plum_Solo%E2%84%A2_and_Plum_Duo%E2%84%A2_Precision_IV_Pumps\" >ICU Medical Launched Its New Category of Infusion Devices With FDA Clearances of Plum Solo\u2122 and Plum Duo\u2122 Precision IV Pumps<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical\/#Anaconda_Biomed_Enrolled_First_US_Patient_in_the_ATHENA_Clinical_Trial_Evaluating_ANA_Funnel_Catheter_for_Ischemic_Stroke_Treatment\" >Anaconda Biomed Enrolled First U.S. Patient in the ATHENA Clinical Trial Evaluating ANA Funnel Catheter for Ischemic Stroke Treatment&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical\/#OrthoPediatrics_Corp_Expanded_Scoliosis_Portfolio_with_Launch_of_VerteGlide%E2%84%A2_System\" >OrthoPediatrics Corp. Expanded Scoliosis Portfolio with Launch of VerteGlide\u2122 System<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical\/#3D_Systems_Solution_Enabled_Worlds_First_Facial_Implant_Manufacturing_at_Point-of-Care\" >3D Systems\u2019 Solution Enabled World\u2019s First Facial Implant Manufacturing at Point-of-Care<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-ventris-medical-received-additional-fda-clearance-for-backpack-bone-graft-in-the-intervertebral-disc-space-nbsp\"><span class=\"ez-toc-section\" id=\"Ventris_Medical_Received_Additional_FDA_Clearance_for_Backpack%C2%AE_Bone_Graft_in_the_Intervertebral_Disc_Space\"><\/span><strong>Ventris Medical Received Additional FDA Clearance for Backpack\u00ae Bone Graft in the Intervertebral Disc Space&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On April 08, 2025, Ventris Medical, a privately held leader in orthobiologics and tissue regeneration, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Backpack\u00ae product for use in the Intervertebral Disc Space. Backpack\u00ae introduces a new class of biomaterials designed to optimize cell proliferation and enhance bone formation, making it ideal for orthopedic and spinal fusion procedures. The product is available in two versions: one featuring a collagen mesh pouch filled with osteoinductive Allocell\u00ae AF fibers, and the other containing surface-activated Amplify\u00ae granules.<\/p>\n\n\n\n<p><em>Russell Cook, CEO of Ventris Medical commented, &#8220;We are very pleased to receive FDA clearance for both the Backpack\u00ae AF and Backpack\u00ae AMP Bone Graft Systems. This graft containment technology is the first of its kind and represents a huge step forward in the bone graft technology available in today&#8217;s market. Backpack\u00ae combines 2 heavily studied components; osteoinductive allograft fibers and our patented surface activated biphasic mineral components and places them in a biologic containment system providing an anti-migration feature not found in any other bone graft offering. Our company mission is to continue to develop next generational devices that bring excitement to the surgeon community as well as our distribution partners.&#8221;<\/em><\/p>\n\n\n\n<p><em>John Brunelle, PhD, COO of Ventris Medical added: &#8220;The Backpack\u00ae technology platform is our latest venture in enhancing the surgeon experience and fusion outcomes. The sophisticated design of the containment system allows for precise delivery and retention of our clinically validated biphasic granules and allograft fibers, ensuring a more consistent healing response at the fusion site. This latest milestone establishes yet another platform for future product developments and further validates Ventris as a key innovator in the orthobiologics space.&#8221;<\/em><\/p>\n\n\n\n<p>Backpack\u00ae AF with Allocell\u00ae AF Allograft Fibers features a unique 100% biologic graft system, where osteoinductive allograft fibers are fully enclosed within a collagen mesh pouch. This innovative design is the first of its kind, with both the containment pouch and allograft fibers contributing to the bone remodeling process at the graft site. The Allocell\u00ae AF allograft fill provides a scaffold-like structure that supports bone cell attachment and proliferation, facilitating the natural healing process. Additionally, the osteoinductive properties of the Allocell\u00ae AF fibers actively promote the differentiation of stem cells into bone-forming cells, enhancing bone regeneration. Supplied in a ported pouch for easy hydration, Backpack\u00ae AF is ready for immediate use, streamlining the surgical procedure.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/bone-grafts-and-substitutes-market\"><strong>Bone Graft and Substitutes Market Report<\/strong><\/a>\u201d, the global bone graft and substitutes market was valued at <strong>USD 3,786.25 million<\/strong> in 2024, growing at a <strong>CAGR of 5.88%<\/strong> during the forecast period from 2025 to 2032 to reach <strong>USD 5,957.71 million<\/strong> by 2032. The increasing prevalence of bone-related disorders and trauma cases, coupled with a rising demand for bone grafts in dentistry, is significantly boosting the global market for bone grafts and substitutes. As bone diseases such as osteoporosis and bone fractures become more common, particularly among the aging population, the need for effective bone regeneration and repair solutions has surged. The growing geriatric population, which is more prone to bone degeneration, fractures, and joint issues, further drives demand for bone grafts, especially in orthopedic and dental procedures. Additionally, the increase in product development activities, with innovations in synthetic, allograft, and xenograft materials, is enhancing the effectiveness and availability of bone graft substitutes. These factors collectively contribute to the expansion of the bone graft and substitutes market, with more advanced, biocompatible, and cost-effective solutions being introduced to meet the rising demand during the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-orthocell-received-us-fda-510-k-clearance-for-remplir-nerve-repair-product-preparing-for-market-launch-nbsp\"><span class=\"ez-toc-section\" id=\"Orthocell_Received_US_FDA_510k_Clearance_for_Remplir%E2%84%A2_Nerve_Repair_Product_Preparing_for_Market_Launch\"><\/span><strong>Orthocell Received US FDA 510(k) Clearance for Remplir\u2122 Nerve Repair Product, Preparing for Market Launch&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On April 04, 2025, Orthocell is pleased to announce that the US Food and Drug Administration (FDA) has granted regulatory clearance under the 510(k) pathway for its innovative nerve repair product, Remplir\u2122. This significant milestone opens the door for Orthocell to enter the rapidly growing US nerve repair market, which is valued at approximately US$1.6 billion. The company is strategically advancing its US market launch, with a robust production ramp-up already in progress.<\/p>\n\n\n\n<p><em>Orthocell CEO and MD, Paul Anderson, said, \u201cI\u2019m delighted to announce we have received FDA clearance for our market-leading nerve repair product. We have been preparing in advance for this pivotal milestone, ramping up production from our facility in Perth and we have significant levels of inventory in place to deliver on early sales orders. Our sales, marketing and education team have made great progress identifying key opinion leaders, reputable reference sites and, most importantly, the distributors that we will work with to get Remplir into surgeons\u2019 hands. We expect strong product adoption in the US, having experienced rapid sales traction in existing markets driven by the excellent feedback from surgeons in Australia, New Zealand and Singapore\u201d<\/em><\/p>\n\n\n\n<p>Orthocell has established a comprehensive operational infrastructure, including outsourced warehousing, order processing, and shipment systems, to ensure seamless delivery and support for customer sales orders. This regulatory achievement positions Orthocell to capitalize on the expanding demand for advanced nerve repair solutions in the United States.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/nerve-repair-and-regeneration-market\"><strong>Nerve Repair And Regeneration Market Report<\/strong><\/a>\u201d, the global nerve repair and regeneration market was valued at USD 6,497.47 million in 2023, growing at a CAGR of 9.31% during the forecast period from 2024 to 2030. The increase in demand for nerve repair and regeneration products is predominantly attributed to the increasing incidence of nerve injuries, rising prevalence of lifestyle disorders such as diabetes and hypertension, and others. Moreover, technological advancements in the nerve repair product portfolio and high product approvals in recent times, among others are also some of the factors contributing to the global market growth for nerve repair and regeneration. Therefore, the above mentioned factors are expected to propel the overall market growth of the nerve repair and regeneration market in the forthcoming years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-icu-medical-launched-its-new-category-of-infusion-devices-with-fda-clearances-of-plum-solo-and-plum-duo-precision-iv-pumps\"><span class=\"ez-toc-section\" id=\"ICU_Medical_Launched_Its_New_Category_of_Infusion_Devices_With_FDA_Clearances_of_Plum_Solo%E2%84%A2_and_Plum_Duo%E2%84%A2_Precision_IV_Pumps\"><\/span><strong>ICU Medical Launched Its New Category of Infusion Devices With FDA Clearances of Plum Solo\u2122 and Plum Duo\u2122 Precision IV Pumps<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On April 7, 2025, ICU Medical Inc., a global leader in innovative medical devices, has received 510(k) regulatory clearance from the U.S. FDA for its Plum Solo\u2122 precision IV pump. This single-channel addition complements the dual-channel Plum Duo\u2122. Additionally, ICU Medical secured 510(k) clearance for updated versions of the Plum Duo precision IV pump and LifeShield\u2122 infusion safety software. These clearances mark the initial launch of the ICU Medical IV Performance Platform, introducing a new category of precision IV pumps and expanding the platform&#8217;s capabilities.<\/p>\n\n\n\n<p>Unlike traditional pumps that depend on specific setups and conditions for precise delivery, precision IV pumps are engineered to reduce delivery variability and meet the growing demand for accurate data in modern patient care. Leveraging the innovative cassette technology from the Best in KLAS award-winning Plum 360\u2122, the Plum Solo and Plum Duo precision IV pumps deliver \u00b13% accuracy in real-world conditions. These pumps eliminate the infusion inconsistencies typical of traditional devices, offering clinicians predictable performance and dependable infusion documentation.<\/p>\n\n\n\n<p><em>\u201cPrecision IV pumps represent a critical step forward for infusion therapy,\u201d said Chad Jansen, corporate vice president and general manager of ICU Medical Infusion Systems. \u201cWith the Plum Solo and Plum Duo, we\u2019re introducing more than just a new device category\u2014we\u2019re setting a new standard. Healthcare teams can now trust not only the delivery of their medications but also the infusion data that supports their decisions, knowing it reflects what patients actually receive.\u201d<\/em><\/p>\n\n\n\n<p>The Plum Solo and Plum Duo offer healthcare systems the flexibility to select the ideal configuration for their infusion needs, optimizing device footprint without sacrificing performance or safety. Both devices are compatible with whole blood and blood products, delivering consistent \u00b13% accuracy. They also eliminate variability caused by external factors such as infusion setup, temperature, or hospital elevation, ensuring reliable and precise infusion delivery in diverse clinical environments.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/infusion-pumps-market\"><strong>Infusion Pumps Market Report<\/strong><\/a>\u201d, the infusion pumps market was valued at USD 13.80 billion in 2023, growing at a <strong>CAGR of 9.54%<\/strong> during the forecast period from 2024 to 2030, to reach USD 23.85 billion by 2030. This rise in chronic conditions often requires prolonged and precise medication management, which infusion pumps can provide. These devices ensure accurate and consistent delivery of medications, vital for managing complex treatment regimens associated with chronic diseases. Additionally, infusion pumps, particularly those designed with advanced safety features and sterile pathways, play a crucial role in minimizing the risk of infections in hospitals. The demand for infusion pumps that enhance patient safety by reducing the incidence of HAIs is a strong driver in the market. Infusion pumps are essential in surgical settings for administering anesthesia, pain management, and post-operative care. The need for precise and controlled delivery of medications during and after surgery drives the demand for sophisticated infusion pump systems. Furthermore, infusion pumps that support remote monitoring enable healthcare providers to manage patients\u2019 conditions effectively from a distance. This capability is especially crucial for chronic disease management and long-term therapies. The increased demand for remote patient monitoring solutions, therefore, significantly boosts the market for infusion pumps. Additionally, the continuous influx of new products and technologies ensures that the market remains dynamic and innovative, during the forecast period from 2024 to 2030.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-anaconda-biomed-enrolled-first-u-s-patient-in-the-athena-clinical-trial-evaluating-ana-funnel-catheter-for-ischemic-stroke-treatment-nbsp\"><span class=\"ez-toc-section\" id=\"Anaconda_Biomed_Enrolled_First_US_Patient_in_the_ATHENA_Clinical_Trial_Evaluating_ANA_Funnel_Catheter_for_Ischemic_Stroke_Treatment\"><\/span><strong>Anaconda Biomed Enrolled First U.S. Patient in the ATHENA Clinical Trial Evaluating ANA Funnel Catheter for Ischemic Stroke Treatment&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On April 3, 2025, Anaconda Biomed, S.L., a medical technology company focused on developing next-generation neurothrombectomy devices, announced the enrollment and treatment of the first U.S. patient in its ATHENA clinical trial. The procedure was performed by Dr. Shahram Majidi, Associate Professor of Neurosurgery, Neurology, and Radiology at the Icahn School of Medicine at Mount Sinai, New York.<\/p>\n\n\n\n<p>ATHENA is a global, randomized pivotal study involving 327 patients, designed to evaluate the safety and effectiveness of Anaconda&#8217;s proprietary ANA Funnel Catheter\u2122. The device is intended for use during stent retriever-based thrombectomy to aid in clot removal by restricting blood flow during retrieval. This allows for simultaneous aspiration and reduces the risk of clot fragmentation at capture in patients with large vessel occlusion acute ischemic stroke.<\/p>\n\n\n\n<p>Anaconda\u2019s funnel catheter featured the largest capture diameter then available for neuroendovascular thrombectomy. Feasibility studies conducted with the device demonstrated high rates of reperfusion and first-pass success, along with a strong safety profile \u2013 data that had been instrumental in supporting the company\u2019s Investigational Device Exemption (IDE) submission. In September 2024, Anaconda received IDE approval from the U.S. Food and Drug Administration to evaluate the ANA Funnel Catheter in the ATHENA trial.<\/p>\n\n\n\n<p><em>\u201cWe have long recognized the impact of fast and complete reperfusion in stroke patients, and we are delighted to have initiated this important clinical trial for examining the role that flow restriction with funnel catheter can play in enhancing endovascular thrombectomy and potentially improving outcomes for stroke patients,&#8221; said Dr. Majidi.<\/em><\/p>\n\n\n\n<p>The ANA5\u2122 is a funnel catheter designed to enhance neurovascular procedures by facilitating the delivery of intravascular devices, including stent retrievers and microcatheters. It features a radiopaque, self-expanding funnel that is coated with a continuous sealing layer, allowing for temporary local flow restriction upon deployment. This design helps optimize the efficiency of procedures by providing better control during clot retrieval and other neurovascular interventions.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/neurovascular-thrombectomy-devices-market\"><strong>Neurovascular Thrombectomy Devices\/Neurothrombectomy Devices Market Report<\/strong><\/a>\u201d, global Neurovascular Thrombectomy Devices\/Neurothrombectomy Devices Market was valued at <strong>USD 722.78 million<\/strong> in 2023, growing at a <strong>CAGR of 6.15%<\/strong> during the forecast period from 2024 to 2030 to reach <strong>USD 1033.33 million<\/strong> by 2030. The rise in demand for Neurovascular Thrombectomy Devices\/Neurothrombectomy Devices is predominantly imputed to the rising prevalence of neurovascular disorder across the globe which require Neurovascular Thrombectomy Devices\/Neurothrombectomy Devices for their treatment such as ischemic stroke and hemorrhagic stroke, growing burden of old age population. In addition, shifting key players focus towards development of technologically advanced product and initiatives to increase awareness regarding neurovascular diseases and their prevention are some of the factors among others that are likely to upsurge the market for Neurovascular Thrombectomy Devices\/Neurothrombectomy Devices.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-orthopediatrics-corp-expanded-scoliosis-portfolio-with-launch-of-verteglide-system\"><span class=\"ez-toc-section\" id=\"OrthoPediatrics_Corp_Expanded_Scoliosis_Portfolio_with_Launch_of_VerteGlide%E2%84%A2_System\"><\/span><strong>OrthoPediatrics Corp. Expanded Scoliosis Portfolio with Launch of VerteGlide\u2122 System<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On April 8, 2025, OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis (\u201cEOS\u201d). This marked the company\u2019s 80th system designed to address musculoskeletal issues in children.<\/p>\n\n\n\n<p>VerteGlide was a guided growth technology developed for children with Early Onset Scoliosis, a severe and sometimes life-threatening condition affecting kids under the age of 10, who often experienced pulmonary and digestive dysfunction due to the deformity. VerteGlide represented the second in a series of technologies OrthoPediatrics was developing to meet the needs of this unique patient population suffering from the debilitating and life-threatening consequences of EOS. With its unique design, the VerteGlide Spinal Growth Guidance System was intended to allow for deformity correction while minimizing the number of repeat surgeries needed until skeletal maturity. Following recent FDA clearance of the device, the Company prepared for a limited launch and anticipated beginning initial surgeries with select children&#8217;s centers during the summer.<\/p>\n\n\n\n<p><em>OrthoPediatrics Scoliosis division President, Greg Odle commented \u201cWe are excited to introduce another new product to treat children with EOS. The team has been working with key opinion leaders from the surgeon community to identify new technologies that will help this particularly vulnerable patient population. VerteGlide\u2019s launch represents our commitment to treating the entire disease state of scoliosis.\u201d<\/em><\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/adult-spinal-deformity-market\"><strong>Adult Spinal Deformity Market Report<\/strong><\/a>\u201d, the Adult Spinal Deformity (ASD) market is estimated to grow at a <strong>CAGR of 5.57%<\/strong> during the forecast period from 2025 to 2032. The demand for adult spinal deformity is primarily being boosted by the increasing prevalence of spinal cord injuries and disorders around the globe. Additionally, increasing incidences of obesity and sedentary lifestyles and growing advancement in surgical techniques and technologies are some of the key factors, which are contributing to the growth of the adult spinal deformity market during the forecast period from 2025 to 2032.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-3d-systems-solution-enabled-world-s-first-facial-implant-manufacturing-at-point-of-care\"><span class=\"ez-toc-section\" id=\"3D_Systems_Solution_Enabled_Worlds_First_Facial_Implant_Manufacturing_at_Point-of-Care\"><\/span><strong>3D Systems\u2019 Solution Enabled World\u2019s First Facial Implant Manufacturing at Point-of-Care<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On April 8, 2025, 3D Systems announced that, in collaboration with University Hospital Basel (Switzerland), the Company\u2019s unique point-of-care additive manufacturing solution had been used to design and produce the world\u2019s first Medical Device Regulation (MDR)-compliant 3D-printed PEEK facial implant. Prof. Florian Thieringer and Dr. Neha Sharma, along with their team of biomedical engineers, had successfully designed and manufactured a custom device to address a patient\u2019s unique needs using 3D Systems\u2019 technology and manufacturing expertise. The implant had been used in a successful surgery completed at the hospital on March 18, 2025. Production of the first MDR-compliant facial implant had been completed using VESTAKEEP\u00ae i4 3DF PEEK by Evonik on 3D Systems\u2019 EXT 220 MED. The cleanroom-based architecture of the printer and simplified post-processing workflows had enabled efficient production of patient-specific medical devices directly at the hospital.<\/p>\n\n\n\n<p>For more than a decade, surgeons had used VSP\u00ae surgical planning solutions that combined best-in-class digital workflows with the industry\u2019s broadest additive manufacturing portfolio of printers and materials to deliver comprehensive patient-matched solutions. Bringing together surgeons, engineers, and technology in the clinical setting had allowed for the immediate development of patient-specific treatments, overcoming the limitations of standard medical devices. As a result, healthcare providers had improved outcomes, increased efficiency, and lowered the cost of care.<\/p>\n\n\n\n<p><em>\u201cOur goal is always to provide the best possible care for our patients,\u201d said Prof. Thieringer. \u201cBeing directly involved in both the design and manufacturing of patient-specific implants \u2014 right here in our hospital \u2014 allows us to tailor treatments precisely to individual needs, respond faster, and improve surgical outcomes. The ability to produce implants on demand represents a new era in personalized care.\u201d<\/em><\/p>\n\n\n\n<p>The first 3D-printed PEEK facial implant, manufactured at the point-of-care using 3D Systems\u2019 EXT 220 MED, represents a breakthrough in personalized medical solutions. This innovative approach enables close collaboration between surgeons, engineers, and technology, allowing for the creation of tailored implants that address the unique and complex needs of individual patients. By producing the implant on-site, the process ensures faster, more precise solutions for facial reconstruction and other medical procedures.<\/p>\n\n\n\n<p>According to DelveInsight\u2019s \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/facial-implants-market\"><strong>Facial Implants Market Report<\/strong><\/a>\u201d, the facial implants market was valued at USD 2.56 billion in 2023, growing at a <strong>CAGR of 8.02%<\/strong> during the forecast period from 2024 to 2030 to reach USD 4.06 billion by 2030. The facial implants market is experiencing significant growth due to the increasing instances of acute &amp; chronic disorders including dental disorders, rising product developmental activities, growing preference for minimally invasive procedures, and availability of a wide variety of facial implants that are acting as major factors contributing to the overall growth of the facial implants market during the forecast period from 2024 to 2030.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ventris Medical Received Additional FDA Clearance for Backpack\u00ae Bone Graft in the Intervertebral Disc Space&nbsp; On April 08, 2025, Ventris Medical, a privately held leader in orthobiologics and tissue regeneration, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Backpack\u00ae product for use in the Intervertebral Disc Space. [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":31466,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[22508,22507,20634,17022,2753,17021,16975,19163],"industry":[17226],"therapeutic_areas":[17241,17245],"class_list":["post-31464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-adult-spinal-deformity","tag-bone-graft-and-substitutes","tag-facial-implants","tag-infusion-pumps","tag-medical-device","tag-medical-devices-market","tag-medtech-market","tag-nerve-repair-and-regeneration","industry-medical-devices","therapeutic_areas-musculoskeletal","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Ventris Medical, Orthocell, ICU Medical<\/title>\n<meta name=\"description\" content=\"Ventris Medical\u2019s Backpack Bone Graft; Orthocell\u2019s Remplir\u2122 Nerve Repair Product; ICU Medical\u2019s Plum Solo\u2122 and Plum Duo\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Ventris Medical, Orthocell, ICU Medical\" \/>\n<meta property=\"og:description\" content=\"Ventris Medical\u2019s Backpack Bone Graft; Orthocell\u2019s Remplir\u2122 Nerve Repair Product; ICU Medical\u2019s Plum Solo\u2122 and Plum Duo\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-10T11:40:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-10T11:40:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/10170932\/medtech-news-for-ventris-medical-orthocell-icu-medical.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Ventris Medical, Orthocell, ICU Medical","description":"Ventris Medical\u2019s Backpack Bone Graft; Orthocell\u2019s Remplir\u2122 Nerve Repair Product; ICU Medical\u2019s Plum Solo\u2122 and Plum Duo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Ventris Medical, Orthocell, ICU Medical","og_description":"Ventris Medical\u2019s Backpack Bone Graft; Orthocell\u2019s Remplir\u2122 Nerve Repair Product; ICU Medical\u2019s Plum Solo\u2122 and Plum Duo","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-04-10T11:40:01+00:00","article_modified_time":"2025-04-10T11:40:02+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/10170932\/medtech-news-for-ventris-medical-orthocell-icu-medical.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical","name":"MedTech News | Ventris Medical, Orthocell, ICU Medical","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/10170932\/medtech-news-for-ventris-medical-orthocell-icu-medical.png","datePublished":"2025-04-10T11:40:01+00:00","dateModified":"2025-04-10T11:40:02+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Ventris Medical\u2019s Backpack Bone Graft; Orthocell\u2019s Remplir\u2122 Nerve Repair Product; ICU Medical\u2019s Plum Solo\u2122 and Plum Duo","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-ventris-medical-orthocell-icu-medical#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/10170932\/medtech-news-for-ventris-medical-orthocell-icu-medical.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/10170932\/medtech-news-for-ventris-medical-orthocell-icu-medical.png","width":772,"height":482,"caption":"medtech-news-for-ventris-medical-orthocell-icu-medical"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/04\/10170932\/medtech-news-for-ventris-medical-orthocell-icu-medical-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Adult Spinal Deformity<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bone Graft and Substitutes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Facial Implants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Infusion Pumps<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nerve Repair and Regeneration<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Adult Spinal Deformity<\/span>","<span class=\"advgb-post-tax-term\">Bone Graft and Substitutes<\/span>","<span class=\"advgb-post-tax-term\">Facial Implants<\/span>","<span class=\"advgb-post-tax-term\">Infusion Pumps<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Nerve Repair and Regeneration<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Apr 10, 2025","modified":"Updated on Apr 10, 2025"},"absolute_dates_time":{"created":"Posted on Apr 10, 2025 5:10 pm","modified":"Updated on Apr 10, 2025 5:10 pm"},"featured_img_caption":"medtech-news-for-ventris-medical-orthocell-icu-medical","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31464"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31464\/revisions"}],"predecessor-version":[{"id":31465,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31464\/revisions\/31465"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31466"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31464"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31464"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}